(603235)"JIANGXI TIANXIN PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 603235 · · 20 pages · Chinese
Summary by 6ix AI
The report confirms the accuracy and completeness of the financial information provided, with no audit conducted for the quarter. Key financial data includes revenue and net profit figures, which reflect changes compared to the previous year.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
JiangXi Tianxin Pharmaceutical Co., Ltd. on 6ix
Earlier from JiangXi Tianxin Pharmaceutical
- (603235)"JIANGXI TIANXIN PHARMACEUTICAL CO., LTD."Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
- Announcement on Operating Data for Q2 2026
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Partial Completion of Canceling Special Accounts for Raised Funds
Later from JiangXi Tianxin Pharmaceutical
- (603235)"JIANGXI TIANXIN PHARMACEUTICAL CO., LTD."Announcement on Appointment of Board Secretary
- (603235)"JIANGXI TIANXIN PHARMACEUTICAL CO., LTD."Announcement on Completion of Election of New Board of Directors and Appointment of Senior Executives and Securities Affairs Representative
- (603235)"JIANGXI TIANXIN PHARMACEUTICAL CO., LTD."Announcement on Election of Employee Representative Director for the 4th Board of Directors
- (603235)"JIANGXI TIANXIN PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- (603235)"JIANGXI TIANXIN PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 1st Meeting of the 4th Board of Directors
Follow JiangXi Tianxin Pharmaceutical into a list and get an email when it puts out news.
Follow JiangXi Tianxin Pharmaceutical